Cargando…
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Real-world studies include a broader patient population for a longer duration than randomised controlled trials (RCTs) and can provide relevant insights for clinical practice. PASSPORT was a multicentre, prospective, post-authorisation study of patients who were newly prescribed pirfenidone and foll...
Autores principales: | Cottin, Vincent, Koschel, Dirk, Günther, Andreas, Albera, Carlo, Azuma, Arata, Sköld, C. Magnus, Tomassetti, Sara, Hormel, Philip, Stauffer, John L., Strombom, Indiana, Kirchgaessler, Klaus-Uwe, Maher, Toby M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194203/ https://www.ncbi.nlm.nih.gov/pubmed/30364407 http://dx.doi.org/10.1183/23120541.00084-2018 |
Ejemplares similares
-
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
por: Gotfried, Mark H., et al.
Publicado: (2018) -
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019) -
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017) -
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021) -
Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)